Liver cancer combo therapy study halted after just 2 patients
NCT ID NCT04327700
First seen Mar 06, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study tested whether adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. It was designed for patients who had already tried other treatments. However, the study was stopped early after only 2 people enrolled, so no meaningful results were obtained.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.